Identification of new markers and drug target candidates for triple negative brea

三阴性乳腺癌新标记物和候选药物靶标的鉴定

• 批准号: 8049320
• 负责人: METODI V METODIEV
• 金额: $ 4.93万
• 依托单位: UNIVERSITY OF ESSEX
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-07 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8049320
• 关键词: Address; African; African American; Antibodies; Atlases; Bioinformatics; Biological Assay; Biological Markers; DNA; Data; Development; Diagnosis; Diagnostic; Disease; Drug Delivery Systems; Genes; Genomics; Incidence; Label; Malignant - descriptor; Mammary Neoplasms; Mass Spectrum Analysis; Measurement; Membrane; Methods; Molecular Profiling; Neoplasm Metastasis; Positive Lymph Node; Premenopause; Prognostic Marker; Proteins; Proteome; Set protein; Staining method; Stains; Therapeutic; Tissues; Tumor Tissue; Woman; base; cell stroma; cohort; drug discovery; malignant breast neoplasm; neoplastic cell; novel; novel marker; outcome forecast; overexpression; protein expression; triple-negative invasive breast carcinoma; tumor

DESCRIPTION (provided by applicant): Triple negative breast cancer is a particularly malignant and hard to treat type of the disease. At the present there are no established biomarkers and drug targets to aid the diagnosis and prognosis of triple negative breast cancer and to inform rationale- based drug discovery and treatment options. This project will utilize recently developed large-scale post-genomic methods to analyze the proteomes of triple negative breast tumors and establish quantitative protein expression profiles of node- metastatic and non-metastatic tumors. The main objective of the project is to identify and validate proteins which are specifically over expressed in metastatic triple negative breast cancer. Ten metastatic and ten non-metastatic triple negative breast tumors will be profiled at an analytical depth of more than 2,000 proteins. The differentially expressed proteins identified by this large-scale profiling will be validated by immunochemical methods and targeted mass spectrometry assays. The obtained data will provide candidate protein markers and potential drug targets that can be used to develop new, more individualized and more efficient therapies for triple negative breast cancer.

描述（由申请人提供）： 三阴性乳腺癌是一种特别恶性和难以治疗的疾病。目前还没有确定的生物标志物和药物靶点来帮助三阴性乳腺癌的诊断和预后，并告知基于理论的药物发现和治疗选择。该项目将利用最近开发的大规模后基因组方法来分析三阴性乳腺肿瘤的蛋白质组，并建立淋巴结转移性和非转移性肿瘤的定量蛋白质表达谱。该项目的主要目的是鉴定和验证在转移性三阴性乳腺癌中特异性过表达的蛋白质。10例转移性和10例非转移性三阴性乳腺肿瘤将在超过2，000种蛋白质的分析深度下进行分析。将通过免疫化学方法和靶向质谱分析来验证通过这种大规模分析鉴定的差异表达蛋白。获得的数据将提供候选蛋白质标记物和潜在的药物靶点，可用于开发新的，更个性化和更有效的三阴性乳腺癌疗法。